Gut

Appearances can be deceiving: an ulcerated oesophageal lesion

An 82-year-old man with alcohol-related cirrhosis (Child-Pugh class B), complicated by portal hypertension and a history of partial gastrectomy with Billroth I reconstruction for duodenal ulcer ...
Gut

Impairment of Rab7-dependent STING degradation hampers HBV replication but accelerates disease progression in chronic hepatitis B comorbid with MASLD

Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic ...
Gut

Bacterial genomic structural variations in children with autism serve as diagnostic biomarkers

Background Gut microbiota dysbiosis is linked to autism spectrum disorder (ASD) in children. However, the role of bacterial ...
Gut

Are the drugs already on the shelf? Repurposing therapy for pancreatitis

The persistent absence of disease-modifying therapy for recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) represents one of the more conspicuous therapeutic gaps in gastroenterology.
Gut

Parental obesity and risk of metabolic dysfunction associated steatotic liver disease in adult offspring: UK birth cohort study

Background Metabolic dysfunction associated steatotic liver disease (MASLD), the most common chronic liver disease globally, may originate early in life. While maternal obesity is linked to offspring ...
gut.bmj

IDDF2020-ABS-0116 The role of gut microbiome in traditional Chinese medicine syndromes: focusing on the spleen deficiency syndrome

1 Novel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Malaysia 2 ...
gut.bmj

Hepatitis E virus replication in human intestinal cells

Objective Hepatitis E virus (HEV), one of the most common agent of acute hepatitis worldwide, is mainly transmitted enterically, via contaminated water for HEV genotypes 1 (HEV1) and HEV2, or by ...
gut.bmj

KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy

Background CLDN18.2 has emerged as a promising therapeutic target in gastric and gastro-oesophageal junction cancers. However, its clinical efficacy in pancreatic ductal adenocarcinoma (PDAC) has been ...
gut.bmj

KIF1Bβ suppresses hepatocellular carcinoma by transporting and secreting FBLN5 to attenuate the integrin pathway

Background Our previous genome-wide association study (GWAS) identified that chromosome 1p36.22 locus contributes to the risk of hepatocellular carcinoma (HCC). Objective We aimed to identify the ...
gut.bmj

UK key performance indicators and quality assurance standards for colonoscopy

Colonoscopy should be delivered by endoscopists performing high quality procedures. The British Society of Gastroenterology, the UK Joint Advisory Group on GI Endoscopy, and the Association of ...
gut.bmj

Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn’s disease

Objective Intestinal barrier loss is a Crohn’s disease (CD) risk factor. This may be related to increased expression and enzymatic activation of myosin light chain kinase 1 (MLCK1), which increases ...